Shin Nippon Biomedical Laboratories Ltd
TSE:2395
Intrinsic Value
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. [ Read More ]
The intrinsic value of one Shin Nippon Biomedical Laboratories Ltd stock under the Base Case scenario is 2 158 574.53 JPY. Compared to the current market price of 1 483 JPY, Shin Nippon Biomedical Laboratories Ltd is Undervalued by 100%.
Fundamental Analysis
Balance Sheet Decomposition
Shin Nippon Biomedical Laboratories Ltd
| Current Assets | 33.4B |
| Cash & Short-Term Investments | 13B |
| Receivables | 5.6B |
| Other Current Assets | 14.8B |
| Non-Current Assets | 37.9B |
| Long-Term Investments | 12.8B |
| PP&E | 21.3B |
| Intangibles | 2.2B |
| Other Non-Current Assets | 1.6B |
| Current Liabilities | 22.4B |
| Accounts Payable | 562.9m |
| Other Current Liabilities | 21.8B |
| Non-Current Liabilities | 18.8B |
| Long-Term Debt | 18.7B |
| Other Non-Current Liabilities | 141.7m |
Earnings Waterfall
Shin Nippon Biomedical Laboratories Ltd
|
Revenue
|
26.7B
JPY
|
|
Cost of Revenue
|
-12.8B
JPY
|
|
Gross Profit
|
13.9B
JPY
|
|
Operating Expenses
|
-9.9B
JPY
|
|
Operating Income
|
4B
JPY
|
|
Other Expenses
|
1.5B
JPY
|
|
Net Income
|
5.5B
JPY
|
Free Cash Flow Analysis
Shin Nippon Biomedical Laboratories Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Shin Nippon Biomedical Laboratories Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Score
Shin Nippon Biomedical Laboratories Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shin Nippon Biomedical Laboratories Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Shin Nippon Biomedical Laboratories Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shin Nippon Biomedical Laboratories Ltd
According to Wall Street analysts, the average 1-year price target for Shin Nippon Biomedical Laboratories Ltd is 2 856 JPY with a low forecast of 2 828 JPY and a high forecast of 2 940 JPY.
Shareholder Return
Price
Shin Nippon Biomedical Laboratories Ltd
| Average Annual Return | 38.33% |
| Standard Deviation of Annual Returns | 58.12% |
| Max Drawdown | -55% |
| Market Capitalization | 61.7B JPY |
| Shares Outstanding | 41 631 931 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 986 full-time employees. The company went IPO on 2004-03-08. The firm has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
You don't have any saved screeners yet
